Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | JAKARTA 1 & 2: response rapidity & durability

Ruben Mesa • 8 Jun 2020
EHA 2020
Myelofibrosis Fedratinib
JAKARTA JAKARTA2

Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the rapidity and durability of response, in the JAKARTA1 (NCT01437787) and JAKARTA2 (NCT01523171) studies evaluating fedratinib in patients with intermediate or high-risk myelofibrosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ruben Mesa

2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
2:08
Real-world analysis of the MOST study: factors impacting progression to MF in patients with ET
Ruben Mesa • 9 Dec 2023
2:26
Assessing the impact of momelotinib on transfusion burden in MF: analysis of SIMPLIFY-1 & MOMENTUM
Ruben Mesa • 9 Dec 2023
2:20
Quantifying the anemia benefit of momelotinib in MF: analysis of data from SIMPLIFY-1 & SIMPLIFY-2
Ruben Mesa • 9 Dec 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals